08:00 , Feb 24, 2014 |  BC Week In Review  |  Clinical News

CardioPET: Phase II data

An open-label, Belgian Phase II trial in 15 CAD patients showed that CardioPET was well tolerated. FluoroPharma said image quality was "excellent" and image time as early as 3 minutes post-injection. In the trial, CardioPET...
07:00 , May 23, 2011 |  BC Week In Review  |  Company News

Commercial E Waste Management, FluoroPharma deal

FluoroPharma completed its reverse merger with Commercial E Waste Management to form FluoroPharma Medical Inc. (OTCBB:CEWM). Under the deal, FluoroPharma Inc. shareholders received about 13.9 million FluoroPharma Medical shares and 661,617 warrants to purchase shares...
07:00 , Sep 15, 2008 |  BC Week In Review  |  Clinical News

FluoroPharma preclinical data

In human prostate tumor cell lines, CardioPET had high uptakes that increased as a function of time. At 30, 60 and 90 minutes, CardioPET uptake increased 350%, 600% and 700% compared with control, respectively. CardioPET...
07:00 , Oct 2, 2006 |  BC Week In Review  |  Clinical News

CardioPET: Phase I started

FluoroPharma began an open-label, U.S. Phase I trial in 18 healthy volunteers. FluoroPharma Inc. , Boston, Mass.   Product: CardioPET   Business: Diagnostic   Molecular target: Not applicable   Description: Positron emission tomography (PET) imaging...